S031 Melanoma in 2027
DESCRIPTION
This session will tackle challenges and controversies of today’s melanoma landscape that inform national guidelines (NCCN/AAD) to optimize patient outcomes. Hot topics include: clinician overdetection and pathology overinterpretation of low-risk melanocytic neoplasms, international dermatopathology efforts to relabel melanoma in situ, bedside tools to reduce clinician overbiopsy, worldwide surgical de-escalation trials, imiquimod for lentigo maligna, how neoadjuvant approaches to cutaneous melanoma (upfront immunotherapy over surgery) impact skin biopsy and baseline imaging, gene expression profiling for prognosis and sentinel lymph node biopsy (SLNB) risk prediction, newer multivariable SLNB risk nomograms, adjuvant therapy for patients with stage II disease, and germline genetic testing.
LEARNING OBJECTIVES
Apply current NCCN and AAD cutaneous melanoma guidelines to clinical practice.
Recognize limitations and benefits of various diagnostic modalities and prognostic tests, including bedside imaging and clinicopathologic nomograms and gene expression profiling for SLNB risk prediction.
Describe the role of adjuvant therapy for resected stage II and III melanoma and how neoadjuvant approaches are transforming cutaneous melanoma biopsy, pathology interpretation, and clinical management.
SCHEDULE
1:00 PM
Introduction to NCCN 2027 melanoma guideline updates for dermatologists
Susan M. Swetter, MD, FAAD
1:15 PM
Pathology assessment and proposed re-labeling of melanoma In situ
Michael Tetzlaff, MD, PhD
1:35 PM
Tools for bedside diagnosis of melanoma to reduce overbiopsy: what’s promising and what isn’t
Jennifer A. Stein, MD, PhD, FAAD
1:55 PM
Panel Q&A
2:05 PM
Gene expression profiling – is it valuable for melanoma prognosis and SLNB risk prediction?
Maija Kiuru, MD, PhD, FAAD
2:25 PM
Biopsy considerations in the era of neoadjuvant therapy and surgical de-escalation trials – is less more?
2:45 PM
Lentigo maligna/melanoma in situ – should imiquimod be front line to avoid surgical overtreatment?
Kelly C. Nelson, MD, FAAD
3:05 PM
Panel Q&A
3:15 PM
How neoadjuvant approaches will affect cutaneous melanoma management and lessons learned from adjuvant therapy in stage II disease
Hensin Tsao, MD, PhD, FAAD
3:35 PM
Germline genetic testing: when is it relevant and for whom?
Elizabeth Gates Berry, MD, FAAD
3:50 PM
Panel Q&A
DIRECTOR
Susan M. Swetter, MD, FAAD
Stanford University Medical Center and Cancer Institute
SPEAKERS
Elizabeth Gates Berry, MD, FAAD
Oregon Health & Science University; Portland VA Medical Center
Maija Kiuru, MD, PhD, FAAD
Kelly C. Nelson, MD, FAAD
Jennifer A. Stein, MD, PhD, FAAD
Michael Tetzlaff, MD, PhD
Hensin Tsao, MD, PhD, FAAD
Harvard Medical School
DISCLOSURES
Elizabeth Gates Berry, MD, FAAD
Merck & Co., Inc – Advisory Board(Fees); Orlucent – Investigator(Grants/Research Funding);
Maija Kiuru, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Kelly C. Nelson, MD, FAAD
No financial relationships exist with ineligible companies.
Jennifer A. Stein, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Susan M. Swetter, MD, FAAD
No financial relationships exist with ineligible companies.
Michael Tetzlaff, MD, PhD
Merck – Other(Fees); Philogen S.p.A. – Advisory Board(Fees); Regeneron – Advisory Board(Honoraria);
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); UpToDate, Inc. – Other(Honoraria);